Dengue Pipeline Review 2021

Dengue is a viral infection caused by mosquito. The virus responsible for causing dengue, is known as dengue virus (DENV). In some Asian and Latin American countries, severe dengue is a leading cause of serious illness and death. Severe dengue has no specific treatment. Early detection of disease along with proper access to medical care reduces the fatality rates of severe dengue to below 1%. Dengue is found mostly in urban and semi-urban areas and in tropical and sub-tropical climates worldwide.

In recent decades, the global incidence of dengue has grown dramatically. Currently, around half of the world's population is at risk. There are around 100-400 million infections per year. Prevention and control of dengue depends on effective vector control measures. According to data published by WHO, there are around 390 million dengue infections every year, of which 96 million evident clinically (with any severity of disease).

Pharmaceutical companies are focusing on launching drugs to treat dengue. For instance, on November 2019, Takeda Pharmaceutical Company Limited declared the launch of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singen vaccine plant will be applied for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line. The company invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant.

Approximately 70% of pipeline drugs for Dengue are in phase 1 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Dengue.

Report Description

The report on Dengue- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Dengue. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Dengue (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

1. Introduction

• Objectives of the Study
• Definition
• Report Overview
• Dengue Overview

2. Executive Summary
3. Dengue: Pipeline Assessment

• Company Overview
• Product Description
• Status
• Phase
• Study Design
• Route of Administration
• Indication       
• Condition        
• NCT Number              
• Sponsor          
• Collaborator   
• Brief Title         
• Study Start Date         
• Study completion (Estimated/Actual)
• Study Completion Date
• Enrollment     
• Research Location (Listed Location Countries)

4. Dengue: Analysis on Dormant & Discontinued Pipeline Candidates

• Overview
• Product Description
• Reason for Discontinuation

5. Dengue: Additional Key Insights

• Epidemiology Overview: Dengue

6. Dengue: Press Releases, Latest News and Conference Details

Note:

• Table of Content is tentative and subject to change as the research progresses
• The drug candidates are included as examples in the pipeline when this ToC was designed and their status might have changed since then.